HRGN — Harvard Apparatus Regenerative Technology Income Statement
0.000.00%
- $30.41m
- $27.92m
- $0.43m
Annual income statement for Harvard Apparatus Regenerative Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.103 | 0.43 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.079 | 0.16 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.33 | 8.23 | 6.15 | 9.09 | 8.16 |
Operating Profit | -5.33 | -8.23 | -6.15 | -8.99 | -7.73 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
Net Income After Taxes | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.87 | -7.98 | -6.07 | -8.95 | -7.73 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.87 | -7.98 | -6.25 | -9.02 | -7.73 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.553 | -0.833 | -0.551 | -0.67 | -0.523 |